CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · IEX Real-Time Price · USD
5.42
-0.06 (-1.09%)
Apr 26, 2024, 9:30 AM EDT - Market open

CollPlant Biotechnologies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Revenue
10.960.315.646.142.325.010.460.080
Revenue Growth (YoY)
3565.22%-98.09%154.86%164.75%-53.77%982.94%470.37%--
Cost of Revenue
1.990.42.0131.881.660.0500
Gross Profit
8.97-0.113.643.140.443.360.420.080
Selling, General & Admin
66.745.944.673.663.722.473.071.93
Research & Development
10.4810.267.634.074.413.883.914.673.3
Operating Expenses
16.481713.578.738.077.66.377.745.23
Operating Income
-7.51-17.10.07-5.6-7.63-4.25-5.96-7.66-5.23
Interest Expense / Income
-0.49-0.17-0.1703.5320.090.12-0.05
Other Expense / Income
---0.18----0.03-
Pretax Income
-7.02-16.930.24-5.77-11.16-6.25-6.05-7.75-5.18
Net Income
-7.02-16.930.24-5.77-11.16-6.25-6.05-7.75-5.18
Shares Outstanding (Basic)
111110754322
Shares Outstanding (Diluted)
111112754322
Shares Change
3.23%-7.80%73.76%38.12%13.73%64.60%32.36%18.84%-
EPS (Basic)
-0.62-1.530.02-0.84-2.23-1.43-2.27-3.89-3.06
EPS (Diluted)
-0.62-1.530.02-0.84-2.23-1.43-2.27-3.89-3.06
Free Cash Flow
-3.65-15.010.95-4.97-7.16-2.05-5.09-5.52-4.42
Free Cash Flow Per Share
-0.32-1.360.10-0.72-1.44-0.47-1.91-2.74-2.61
Gross Margin
81.83%-33.78%87.18%51.08%18.94%66.91%89.63%100.00%-
Operating Margin
-68.55%-5718.06%0.42%-91.23%-329.21%-84.66%-1286.61%-9433.22%-
Profit Margin
-64.05%-5660.54%1.52%-94.09%-481.62%-124.63%-1306.91%-9552.40%-
Free Cash Flow Margin
-33.30%-5021.40%6.04%-80.98%-309.06%-40.87%-1100.00%-6797.60%-
EBITDA
-6.41-16.020.84-5.11-7.09-3.9-5.73-7.39-5.01
EBITDA Margin
-58.49%-5358.19%5.36%-83.33%-305.95%-77.84%-1236.93%-9105.48%-
Depreciation & Amortization
1.11.080.770.660.540.340.230.240.22
EBIT
-7.51-17.10.07-5.77-7.63-4.25-5.96-7.63-5.23
EBIT Margin
-68.55%-5718.06%0.42%-94.09%-329.21%-84.66%-1286.61%-9401.37%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).